Navigation Links
Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
Date:1/8/2014

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Adheron Therapeutics, a biotechnology company which focuses on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases, announced the completion of the company's Phase 1 clinical trial for its leading Cad-11 inhibitor SDP051.  Cad-11 acts as a key mediator of joint destruction in rheumatoid arthritis, and is also an important contributor to fibrotic pathology. These are disease pathways that Adheron Therapeutics is particularly interested in pursuing.

SDP051 is a humanized monoclonal antibody to Cadherin-11, which acts as an "adhesive" between cells. Changes in Cad-11 interactions can induce cells to produce proteins that influence the cellular environment. The recently completed SDP051 trial was designed to assess the safety and tolerability of an escalating single dose of the compound in healthy volunteers who received SDP051 or placebo. The trial also assessed the pharmacokinetic properties of the protein in vivo.

Results from the Phase 1 trial show that SDP051 is safe and well-tolerated at doses up to 10 mg/kg per day with no evidence of significant side effects.

"The results from this trial meet and even exceed our expectations for safety, and provide evidence for an excellent dosing schedule," said Hari Kumar, CEO of Adheron Therapeutics. "The favorable profile lays the foundation for us to evaluate once monthly dosing in a Phase 2 trial, which we expect to start in 2015."

About Cad-11

Cadherin-11 (Cad-11) is a surface protein expressed on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) in the joints. Cad-11 acts as an "adhesive" between cells, and changes in Cad-11 interactions can induce the cells to produce proteins that influence the cellular environment. Research completed in the laboratory of Michael Brenner, MD, at Brigham and Women's Hospital and Harvard Medical School has implicated Cad-11 in the disease processes leading to rheumatoid arthritis. Work initiated in Dr. Brenner's laboratory by Dr. Sandeep Agarwal, now at Baylor College of Medicine, has also demonstrated that Cad-11 plays a role in diverse fibrotic diseases.

A recent study published in OncoTarget and led by investigators at Georgetown University Medical Center, showed that Cad-11 is significantly over-produced in two very different diseases—rheumatoid arthritis and a variety of cancers, including breast and brain tumors.

For more information: http://explore.georgetown.edu/news/?ID=73435&PageTemplateID=295

About Adheron Therapeutics

Adheron Therapeutics is a biotechnology company focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases. Founded by Dr. Brenner and Dr. Lee of Harvard Medical School, the company is led by industry veterans Bob Baltera (executive chairman) and Hari Kumar, PhD (CEO), and funded by a group of venture investors comprising Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, Amgen Ventures, and SROne.

www.adherontherapeutics.com

Contact:
Jacqueline Wallach
650 283 6617
jacqueline.wallach@gilitycomms.com

Michele Parisi
925 429 1850
mparisi@biocommnetwork.com


'/>"/>
SOURCE Adheron Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Adheron Therapeutics Names New Senior Leadership
2. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
3. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
4. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
5. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
6. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
7. PTC Therapeutics Added to NASDAQ Biotechnology Index
8. Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
9. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
10. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
11. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , ... Compass Research . GGI's mission is to advance global health and highlight the ... need in honor of each clinical trial volunteer. The vision of GGI is to ...
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leading medical education provider of women’s health, primary care, and specialty education, ... for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a six-year ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):